This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Natus Medical Announces Fourth Quarter And Full Year 2011 Results

Natus Medical Incorporated (Nasdaq:BABY) today announced financial results for the fourth quarter and full year ended December 31, 2011.

For the fourth quarter ended December 31, 2011, Natus reported revenue of $64.1 million, compared to $63.2 million reported in the comparable quarter of the previous year. The Company reported a loss of $17.3 million, or $0.60 per share, for the fourth quarter of 2011, compared with net income of $5.2 million, or $0.18 per diluted share, for the fourth quarter of 2010.

For the year ended December 31, 2011, Natus reported revenue of $232.7 million, compared to $218.7 million reported in 2010. Net loss was $11.7 million, or $0.41 per share for the year ended December 31, 2011, compared to net income of $11.9 million, or $0.41 per diluted share in 2010.

Results for the 2011 fourth quarter and full year include a $20 million non-cash goodwill impairment charge for the Company’s European operations.

On a non-GAAP basis the Company reported net income of $4.1 million, or $0.14 per diluted share, for the fourth quarter of 2011, compared with net income of $7.0 million, or $0.24 per diluted share, for the fourth quarter of 2010, and net income of $14.0 million, or $0.47 per diluted share, for the full year 2011, compared with net income of $19.0 million, or $0.65 per diluted share, for the full year 2010.

In commenting on the fourth quarter revenue results, Jim Hawkins, Chief Executive Officer of the Company said, “During the fourth quarter we experienced a strong rebound in our business with revenue of $64.1 million compared to $51.3 million reported for the third quarter and just shy of our $65 million guidance.”

“I am pleased to report that recently acquired Embla Systems had an excellent quarter as did our newborn care group,” added Hawkins. “We continue to expect Embla to be accretive to earnings in 2012, adding approximately eight cents to non-GAAP earnings per share.”

1 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs